Table 1.

Patient characteristics for discovery and validation cohorts

VariableDiscovery cohort (n = 96)Validation cohort (n = 88)P
Age, y .669
 Median4850.5
 Range17-7717-80
Sex .552
 Female38 (39.6)39 (44.3)
 Male58 (60.4)49 (55.7)
BCR-ABL1 at 3 mo, % 1
<1083 (86.5)77 (87.5)
 >1013 (13.5)11 (12.5)
BCR-ABL1 transcript type .084
 b2a238 (39.6)36 (40.9)
 b2a31 (1.0)0 (0.0)
 b3a232 (33.3)39 (44.3)
 Both25 (26.0)12 (13.6)
 e1a20 (0.0)1 (1.1)
Sokal score .458
 High15 (16.9)19 (21.8)
 Intermediate27 (30.3)30 (34.5)
 Low47 (52.8)38 (43.7)
ELTS .442
 High7 (7.9)12 (13.8)
 Intermediate23 (25.8)20 (23.0)
 Low59 (66.3)55 (63.2)
BC progression .447
 Yes5 (5.2)2 (2.3)
 No91 (94.8)86 (97.7)
MMR by 24 mo .279
 Yes79 (82.3)66 (75.0)
 No17 (17.7)22 (25.0)
MR4.5 by 5 y .298
 Yes59 (61.5)47 (53.4)
 No37 (38.5)41 (46.6)
  • Data are n (%) unless otherwise noted.